Randomized trial · people

Tesamorelin shifted liver gene activity in HIV-related fatty liver

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with HIV and fatty liver, the liver benefits seen with tesamorelin in this trial came with matching changes in liver gene activity, including lower inflammation-related genes.

Kind
Randomized trial
Studied in
People
Published
2020
Journal
JCI Insight

What they tested

The team wanted to see which liver gene pathways tesamorelin changes, compared with placebo, in people with HIV who have NAFLD (nonalcoholic fatty liver disease).

How the study was done

A follow-up analysis of a randomized, placebo-controlled 1-year trial in people with HIV and NAFLD, in which tesamorelin had lowered liver fat and kept scarring (fibrosis) from getting worse. The researchers compared paired liver biopsies, taken from the same people, using gene set enrichment analysis, a method that tests whether whole groups of related genes move together.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Compared with placebo, tesamorelin raised the activity of gene sets tied to oxidative phosphorylation, a cell energy process. It lowered gene sets tied to inflammation, tissue repair and cell division. It also pushed up gene sets linked to a better outlook in hepatocellular carcinoma (a liver cancer) and pushed down those linked to a worse outlook. In the tesamorelin group, these shifts tracked with a better fibrosis-related gene score.

What it doesn’t show

This is a secondary look at gene activity in liver tissue, not a new test of clinical outcomes, and the gene changes are signals rather than proof of health effects. It included only people with HIV-related NAFLD.

The paper

Fourman et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo